Analysts expect that Quanterix Corp. (NASDAQ:QTRX) will announce ($0.28) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Quanterix’s earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.23). The company is scheduled to report its next earnings report after the market closes on Wednesday, May 9th.
On average, analysts expect that Quanterix will report full year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.17) to ($1.06). For the next financial year, analysts anticipate that the company will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.69) to ($0.42). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Quanterix.
Get Quanterix alerts:Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.08).
Several equities research analysts have weighed in on the stock. BTIG Research reissued a “buy” rating and set a $26.00 price target on shares of Quanterix in a research report on Sunday, May 13th. ValuEngine raised shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research cut shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.50.
Shares of Quanterix traded up $0.43, reaching $20.08, during trading on Friday, MarketBeat.com reports. The company’s stock had a trading volume of 67,100 shares, compared to its average volume of 109,252. Quanterix has a 52-week low of $15.30 and a 52-week high of $24.81. The stock has a market capitalization of $421.20 million and a price-to-earnings ratio of -2.42.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in Quanterix during the 1st quarter valued at $129,000. Opaleye Management Inc. boosted its position in Quanterix by 130.8% during the 1st quarter. Opaleye Management Inc. now owns 150,000 shares of the company’s stock valued at $2,556,000 after buying an additional 85,000 shares during the period. Citadel Advisors LLC purchased a new stake in Quanterix during the 1st quarter valued at $431,000. BlackRock Inc. purchased a new stake in Quanterix during the 1st quarter valued at $3,439,000. Finally, Northern Trust Corp purchased a new stake in Quanterix during the 1st quarter valued at $894,000. 45.89% of the stock is owned by institutional investors and hedge funds.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Get a free copy of the Zacks research report on Quanterix (QTRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment